Commentary: The mood in the field of antidepressant drug discovery

CNS and Neurological Disorders - Drug Targets

Volumn 10, Issue 7, 2011, Pages 762-763

  Witkin, Jeffrey M ^a  

^a ELI LILLY AND COMPANY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 AMINO 2 (2 CARBOXYCYCLOPROPYL) 3 (XANTHEN 9 YL)PROPIONIC ACID; AMPA RECEPTOR; AMPA RECEPTOR ANTAGONIST; ANTIDEPRESSANT AGENT; GLUTAMIC ACID; IMIPRAMINE; KETAMINE; MAMMALIAN TARGET OF RAPAMYCIN; METABOTROPIC RECEPTOR 2; METABOTROPIC RECEPTOR 3; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; POSTSYNAPTIC DENSITY PROTEIN 95; ZINC;

ARTICLE; BIPOLAR DEPRESSION; DEPRESSION; ELECTROCONVULSIVE THERAPY; HUMAN; MAJOR DEPRESSION; MOOD; NONHUMAN; PRESCRIPTION; REMISSION;

EID: 81155132330     PISSN: 18715273     EISSN: 19963181     Source Type: Journal    
DOI: 10.2174/187152711798072338     Document Type: Article

References (18)

1. Witkin J.M. and Li X. New approaches to the management of major depressive disorders. In: Contemporary Aspects of Biomedical Research: Drug Discovery, Advances in Pharmacology; Enna, S.J.; Williams, M., Eds.; Academic Press: New York, 2009, pp. 347-379.
2. Trivedi, M.H.; Rush, A.J.; Wisniewski, S.R.; Nierenberg, A.A.; Warden, D.; Ritz, L.; Norquist, G.; Howland, R.H.; Lebowitz, B.; McGrath, P.J.; Shores-Wilson, K.; Biggs, M.M.; Balasubramani, G.K.; Fava, M.; STAR*D Study Team. Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice. Am. J. Psychiatry, 2006, 163, 28-40.
3. Berman, R.M.; Cappiello, A.; Anand, A.; Oren, D.A.; Heninger, G.R.; Charney, D.S.; Krystal, J.H. Antidepressant effects of ketamine in depressed patients. Biol. Psychiatry, 2000, 47, 351-354.
4. Zarate, C.A., Jr.; Singh, J.B.; Carlson, P.J.; Brutsche, N.E.; Ameli, R.; Luckenbaugh, D.A.; Charney, D.S.; Manji, H.K. Randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression. Arch. Gen. Psychiatry, 2006, 63, 856-864.
5. Ostroff, R.; Gonzales, M.; Sanacora, G. Antidepressant effect of ketamine during ECT. Am. J. Psychiatry, 2005, 162, 1385-1386.
6. Diazgranados, N.; Ibrahim, L.; Brutsche, N.E.; Newberg, A.; Kronstein, P.; Khalife, S.; Kammerer, W.A.; Quezado, Z.; Luckenbaugh, D.A.; Salvadore, G.; Machado-Vieira, R.; Manji, H.K.; Zarate, C.A., Jr. A randomized add-on trial of an N-methyl-D-aspartate antagonist in treatment-resistant bipolar depression. Arch. Gen. Psychiatry, 2010, 67, 793-802.
7. Skolnick, P.; Popik, P.; Trullas, R. Glutamate Based Antidepressants: 20 Years On. Trends Pharmacol. Sci., 2009, 11, 563-569.
8. Preskorn, S.H.; Baker, B.; Kolluri, S.; Menniti, F.S.; Krams, M.; Landen, J.W. An innovative design to establish proof of concept of the antidepressant effects of the NR2B subunit selective N-methyl-D-aspartate antagonist, CP-101,606, in patients with treatment-refractory major depressive disorder. J. Clin. Psychopharmacol., 2008, 28, 631-637.
9. Wilkins, L.K.; Girard, T.A.; Cheyne, J.A. Ketamine as a primary predictor of out-of-body experiences associated with multiple substance use. Conscious Cogn., 2011, 20(3), 943-950.
10. Siwek, M.; Dudek, D.; Paul, I.A.; Sowa-Kućma, M.; Zieba, A.; Popik, P.; Pilc, A.; Nowak, G. Zinc supplementation augments efficacy of imipramine in treatment resistant patients: a double blind, placebo-controlled study. J. Affect. Disord., 2009, 118, 187-195.
11. http://www.naurex.com/media/Naurex_Series_A_financing.pdf
12. Maeng, S.; Zarate, C.A., Jr.; Du, J.; Schloesser, R.J.; McCammon, J.; Chen, G.; Manji, H.K. Cellular mechanisms underlying the antidepressant effects of ketamine: role of alpha-amino-3-hydroxy-5-methylisoxazole-4-propionic acid receptors. Biol. Psychiatry, 2008, 63, 349-352.
13. Alt, A.; Nisenbaum, E.S.; Bleakman, D.; Witkin, J.M. A role for AMPA receptors in mood disorders. Biochem. Pharmacol., 2006, 71, 1273-1288.
14. Nisenbaum, E.S.; Witkin, J.M. Positive Allosteric Modulation of AMPA Receptors: A Novel Potential Antidepressant Therapy. In: Glutamate-Based Therapies for Psychiatric Disorders; Skolnick, P., Edr.; Birkhäuser Verlag; Basel, Switzerland, 2010, pg. 39-56.
15. Szewczyk, B.; Poleszak, E.; Sowa-Kućma, M.; Wróbel, A.; Słotwićski, S.; Listos, J.; Wla, P.; Cichy, A.; Siwek, A.; Dybała,M.; Go embiowska, K.; Pilc, A.; Nowak, G. The involvement of serotonergic system in the antidepressant effect of zinc in the forced swim test. Prog. Neuropsychopharmacol. Biol. Psychiatry, 2009, 33, 323-329.
16. Li, N.; Lee, B.; Liu, R.J.; Banasr, M.; Dwyer, J.M.; Iwata, M.; Li, X.Y.; Aghajanian, G.; Duman, R.S. mTOR-dependent synapse formation underlies the rapid antidepressant effects of NMDA antagonists. Science, 2010, 329, 959-964.
17. Dwyer, J.M.; Lepack, A.E.; Duman, R.S. Effectgs of mGluR2/3 blockade on mTOR signaling and synaptic protein expression. Soc. Neurosci. Abstr., 2011, in press.
18. Autry, A.E.; Adachi, M.; Nosyreva, E.; Na, E.S.; Los, M.F.; Cheng, P.F.; Kavalali, E.T.; Monteggia, L.M. NMDA receptor blockade at rest triggers rapid behavioural antidepressant responses. Nature, 2011, 475, 91-95.